

Clinical trials of irbesartan+ACE inhibitor

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
irbesartan+ACE inhibitor vs ACE inhibitor only			
Tonkon et al. , 2000 n=57/52 follow-up: 12 wk	Irbesartan, 150 mg daily (plus ACE inhibitor) versus Placebo (plus ACE inhibitor)	patients with heart failure (New York Heart Association functional class II and III) and left ventricular ejection fraction (LVEF) <or = 40% received stable doses of ACE inhibitors and diuretics	Parallel groups double blind

More details and results :

- angiotensin-receptor blockers for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q65>
- angiotensin-receptor blockers for heart failure in patients already receiving ACE inhibitor at <http://www.trialresultscenter.org/go-Q68>

References

Tonkon et al., 2000:

Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, Block AJ A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract 2000 Jan-Feb;54:11-4, 16-8 [[10750252](#)]

Entry terms: irbesartan, Aprovel, Avapro, Karvea